Global Amiodarone Market Research Report 2021

Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of irregular heartbeats. This includes ventricular tachycardia (VT), ventricular fibrillation (VF), and wide complex tachycardia, as well as atrial fibrillation and paroxysmal supraventricular tachycardia.

The global Amiodarone market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Amiodarone volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Amiodarone market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Amiodarone Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Tablet Amiodarone
Capsule Amiodarone
Injection Amiodarone

Segment by Application
Cardiac Arrest
Ventricular Tachycardia
Atrial Fibrillation
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Sanofi
Sawai Pharmaceutical
Wyeth Pharmaceuticals(Pfizer)
Mylan Pharmaceuticals
Arrow Pharma Pty Ltd
Roemmers
Cipla Pharmaceutical
Shanghai Pharmaceuticals
North China Pharmaceutical Company
Harbin Pharmaceutical Group